Ma Feng, Liu Yirong, Bai Ming, Li Yangping, Yu Yan, Zhou Meilan, Wang Pengbo, He Lijie, Huang Chen, Wang Hanmin, Sun Shiren
Department of Nephrology, Xijing Hospital, Fourth Military Medical University, Xi׳an, Shaanxi, China.
Department of Nephrology, Xijing Hospital, Fourth Military Medical University, Xi׳an, Shaanxi, China; Department of Nephrology, Xining No. 1 People׳s Hospital, Xining, Qinghai, China.
Am J Med Sci. 2016 Sep;352(3):272-9. doi: 10.1016/j.amjms.2016.06.002. Epub 2016 Jun 11.
The excessive correction of acute hypernatremia is not known to be harmful. This study aimed to evaluate whether a reduction rate of serum sodium (RRSeNa) > 1mEq/L/hour in acute severe hypernatremia is an independent risk factor for mortality in critically ill patients undergoing continuous venovenous hemofiltration (CVVH) treatment.
For this retrospective study, we reviewed records of 75 critically ill patients undergoing CVVH treatment for acute severe hypernatremia between March 2011 and March 2015.
The 28-day mortality rate of all patients was 61.3%. In multivariate Cox regression analyses, a reduction rate of serum sodium (RRSeNa) > 1mEq/L/hour (hazard ratio = 1.89; 95% CI: 1.03-3.47; P = 0.04), Acute Physiology and Chronic Health Evaluation II score and vasopressor dependency (yes or no) had a statistically significantly effect on mortality. Once we excluded patients with an RRSeNa ≤ 0.5mEq/L/hour, only RRSeNa > 1mEq/L/hour (hazard ratio = 2.611; 95% CI: 1.228-5.550; P = 0.013) and vasopressor dependency had a statistically significant influence on mortality in multivariate regression.
In addition to the Acute Physiology and Chronic Health Evaluation II score and vasopressor dependency, the excessive correction of acute severe hypernatremia was possibly associated with mortality in critically ill patients undergoing CVVH treatment. The optimal reduction rate of acute hypernatremia should be extensively studied in critically ill patients.
急性高钠血症的过度纠正是否有害尚不清楚。本研究旨在评估急性重度高钠血症患者血清钠降低速率(RRSeNa)>1mEq/L/小时是否是接受持续静静脉血液滤过(CVVH)治疗的危重症患者死亡的独立危险因素。
在这项回顾性研究中,我们回顾了2011年3月至2015年3月期间75例接受CVVH治疗急性重度高钠血症的危重症患者的记录。
所有患者的28天死亡率为61.3%。在多因素Cox回归分析中,血清钠降低速率(RRSeNa)>1mEq/L/小时(风险比=1.89;95%CI:1.03-3.47;P=0.04)、急性生理与慢性健康状况评分II以及血管升压药依赖(是或否)对死亡率有统计学显著影响。一旦我们排除RRSeNa≤0.5mEq/L/小时的患者,在多因素回归中,只有RRSeNa>1mEq/L/小时(风险比=2.611;95%CI:1.228-5.550;P=0.013)和血管升压药依赖对死亡率有统计学显著影响。
除急性生理与慢性健康状况评分II和血管升压药依赖外,急性重度高钠血症的过度纠正可能与接受CVVH治疗的危重症患者的死亡率相关。急性高钠血症的最佳降低速率应在危重症患者中进行广泛研究。